Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions
PR Newswire
FORT COLLINS, Colo. and BUFFALO, N.Y., Feb. 17, 2021